| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2011057960 |
| Title |
Crystalline Cdc7 Inhibitor Salts. |
| Abstract |
The present invention relates to novel crystalline salts of a CDC7 or CDC7/CDKs inhibitor, to a novel crystal form of the corresponding free base, to a process for their preparation, to hydrates, solvates and polymorphs of such new salt forms, to their use in therapy and to pharmaceutical compositions containing them. Such crystal salts are selected from L-asparate, hemifumarate, hydrochloride, maleate, mesylate, sulfate, L-tartrate or phosphate salts of 5-(2-amino-pyrimidin-4-yl)-2-(2,4-dichloro-phenyl)-1H-pyrrole-3-carboxylic acid amide. |
| Applicant(s) |
Nerviano Medical Sciences S.R.L |
| Representative Drug(s) |
D0G6QW |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2010019967 |
| Title |
Fluorescent Cdk Inhibitors for Treatment of Cancer. |
| Abstract |
Disclosed are molecules and their synthesis,. The fluorescent moiety also facilitates screening, tracking, and pharmacodynamic studies of the drug in a biological system both in vitro and in vivo. |
| Applicant(s) |
Georgetown University Yenugonda |
| Representative Drug(s) |
D01UAL |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2009070567 |
| Title |
2-Fluoropyrazolo[1,5-A]Pyrimidines As Protein Kinase Inhibitors. |
| Abstract |
Pyrazolo[1,5-a]pyrimidine-based inhibitors of various kinase, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions that contain such inhibitors are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 or CHK-1 inhibitor compounds, methods of inhibiting CDK-2 or CHK-1, and methods for treating disease or disease symptoms. |
| Applicant(s) |
Schering Corp |
| Canadian Intellectual Property Office (CIPO) |
| Patent ID |
CA2597193 |
| Title |
Compounds and Uses. |
| Representative Drug(s) |
D0BU1L |
Drug Info
|
N.A. |
[1] |
